ArticleJournal of nanobiotechnology2025
A fibrin gel-loaded Gouqi-derived nanovesicle (GqDNV) repairs the heart after myocardial infarction by inhibiting p38 MAPK/NF-κB p65 pathway.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review.Frontiers in cardiovascular medicine · 2026Pooled it
- Emerging Plant-Derived Exosome-Like Particles Reveal Key Therapeutic Benefits. A Comprehensive Review of Evidence.International journal of nanomedicine · 2025Pooled it
- Systematic discovery of immunomodulatory plant-derived nanoparticles reveals RNA-mediated macrophage reprogramming.Bioactive materials · 2026Article
- Mechanisms and Translational Potential of Plant-Derived Extracellular Vesicles in Cardiovascular Disease.Cells · 2026Review
- Plant-derived extracellular vesicles as emerging cardioprotective agents for cardiovascular diseases.Journal of nanobiotechnology · 2026Review
- From targeted delivery to inflammation suppression: engineering plant exosomes for heart failure therapy post-infarction.Materials today. Bio · 2026Article
- Engineering Strategies for Plant-Derived Extracellular Vesicles: Modification, Drug Delivery Performance, and Synergistic Effects with Gel Composite Systems.Pharmaceutics · 2026Review
- Therapeutic strategies for ischemic heart disease with natural product-based nanomedicines.Journal of nanobiotechnology · 2026Review
- TRPC6 governs brown adipose thermogenesis via a BMPR2-p38 MAPK signaling axis.Molecular metabolism · 2026Article
- Oral plant-derived exosome-like nanovesicles: a new therapeutic perspective for intestinal diseases.Frontiers in pharmacology · 2026Review
- Ginseng-derived exosomes loaded in fibrin gel promote retinal ganglion cell survival in glaucoma by exerting anti-inflammatory effects through modulating microglial polarization.Regenerative biomaterials · 2026Article
- Bioengineering Applications of Chinese Herbal Medicine-Derived Exosomes in Cardiovascular Diseases: Mechanisms and Translational Prospects.Drug design, development and therapy · 2026Review
- Plant-derived extracellular vesicles in skin and bone tissue engineering: current status, challenges, and future perspectives.Frontiers in bioengineering and biotechnology · 2026Review
- Article
- The Use of Plant-Derived Extracellular Vesicles in Regenerative Medicine Applied to Cutaneous Wound Healing.Pharmaceutics · 2025Review
- Mechanism and research progress of MAPK signaling pathway in myocardial fibrosis.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The restoration of cardiac function post-myocardial infarction (MI) remains a significant clinical challenge. Emerging evidence indicates that Goji berries ("Gouqi" in Chinese) and their extracts exhibit substantial cardioprotective properties. Here, we introduce fibrin gel-loaded Gouqi-derived nanovesicles (GqDNVs-gel) as a delivery system targeted at the infarcted myocardium. The application of GqDNVs-gel resulted in a marked improvement in survival rates over a 14-day period post-MI, enhanced cardiac function, reduced infarct size, myocardial apoptosis, and excessive fibrosis, and facilitated endogenous repair. Through a combination of transcriptomics and proteomics analyses, alongside in vitro and in vivo experiments, we identified that the cardioprotective effect of GqDNVs are mediated through the inhibition of the p38 MAPK-NF-κB p65 signaling pathway. Furthermore, GqDNVs contain abundant bioactive compounds, including proteins, genetic materials, lipids, polysaccharides, and flavonoids. GqDNVs-gel intervention can reshape the post-MI cardiac environment and modulate myocardial lipid metabolism, specifically impacting glycerophospholipid and α-linolenic acid metabolic pathways. The upregulation of the peptide Arg-Thr-Ile-Glu and the downregulation of phosphatidylethanolamine in the hearts of MI mice after GqDNVs-gel intervention may play crucial roles in modulating the associated metabolic pathways. This study is the first to highlight the multifaceted therapeutic effects of GqDNVs-gel, offering a promising strategy for enhancing cardiac function post-MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.